Ionis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US4622221004

SecurityIONS / Ionis Pharmaceuticals, Inc.
InstitutionTocqueville Asset Management L.p.
Latest Disclosed Ownership219,220 shares
Latest Disclosed Value $ 16,461,230
Tocqueville Asset Management L.p. ownership in IONS / Ionis Pharmaceuticals, Inc.

On May 12, 2026 - Tocqueville Asset Management L.p. filed a 13F-HR form disclosing ownership of 219,220 shares of Ionis Pharmaceuticals, Inc. (US:IONS) valued at $16,461,230 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 203,730 shares of Ionis Pharmaceuticals, Inc.. This represents a change in shares of 7.60% during the quarter. The current value of the position is $16,327,506 USD.

Tocqueville Asset Management L.p. has a history of taking positions in derivatives of the underlying security (IONS) in the form of stock options. The firm currently holds call options representing 1,000 of underlying shares valued at $75,090 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IONS / Ionis Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F IONIS PHARMACEUTICALS COM 462222100 219,220 15,490 7.60 16,461 2.13 0.2441
2026-02-12 2025-12-31 13F IONIS PHARMACEUTICALS COM 462222100 203,730 10,685 5.53 16,117 27.62 0.2351
2025-11-13 2025-09-30 13F IONIS PHARMACEUTICALS COM 462222100 193,045 5,700 3.04 12,629 70.62 0.1836
2025-08-12 2025-06-30 13F IONIS PHARMACEUTICALS COM 462222100 187,345 -50 -0.03 7,402 30.94 0.1127
2025-05-13 2025-03-31 13F IONIS PHARMACEUTICALS COM 462222100 187,395 -164,745 -46.78 5,654 -54.08 0.0923
2025-02-10 2024-12-31 13F IONIS PHARMACEUTICALS COM 462222100 352,140 -54,730 -13.45 12,311 -24.47 0.1931
2024-11-08 2024-09-30 13F IONIS PHARMACEUTICALS COM 462222100 406,870 181,800 80.77 16,299 51.96 0.2560
2024-08-12 2024-06-30 13F IONIS PHARMACEUTICALS COM 462222100 225,070 65,690 41.22 10,727 55.25 0.1771
2024-05-09 2024-03-31 13F IONIS PHARMACEUTICALS COM 462222100 159,380 -400 -0.25 6,909 -14.52 0.1129
2024-02-12 2023-12-31 13F IONIS PHARMACEUTICALS COM 462222100 159,780 -1,950 -1.21 8,083 10.18 0.1465
2023-11-09 2023-09-30 13F IONIS PHARMACEUTICALS COM 462222100 161,730 -750 -0.46 7,336 10.05 0.1393
2023-08-11 2023-06-30 13F IONIS PHARMACEUTICALS COM 462222100 162,480 0 0.00 6,667 14.79 0.1194
2023-05-10 2023-03-31 13F IONIS PHARMACEUTICALS COM 462222100 162,480 911 0.56 5,807 -4.83 0.1097
2023-02-09 2022-12-31 13F IONIS PHARMACEUTICALS COM 462222100 161,569 -825 -0.51 6,102 -15.05 0.1159
2022-11-10 2022-09-30 13F IONIS PHARMACEUTICALS COM 462222100 162,394 -211 -0.13 7,183 19.32 0.1464
2022-08-12 2022-06-30 13F IONIS PHARMACEUTICALS COM 462222100 162,605 -4,900 -2.93 6,020 -2.97 0.1101
2022-05-16 2022-03-31 13F Ionis Pharmaceuticals COM 462222100 167,505 -2,900 -1.70 6,204 19.65 0.0937
2022-02-14 2021-12-31 13F IONIS PHARMACEUTICALS COM 462222100 170,405 1,875 1.11 5,185 -8.26 0.0713
2021-11-15 2021-09-30 13F IONIS PHARMACEUTICALS COM 462222100 168,530 -3,670 -2.13 5,652 -17.72 0.0837
2021-08-16 2021-06-30 13F IONIS PHARMACEUTICALS COM 462222100 172,200 -73,292 -29.86 6,869 -37.76 0.0992
2021-05-17 2021-03-31 13F IONIS PHARMACEUTICALS COM 462222100 245,492 -25,405 -9.38 11,037 -27.94 0.1698
2021-02-16 2020-12-31 13F IONIS PHARMACEUTICALS COM 462222100 270,897 -4,935 -1.79 15,317 17.03 0.2557
2020-11-16 2020-09-30 13F IONIS PHARMACEUTICALS COM 462222100 275,832 -2,980 -1.07 13,088 -20.38 0.2504
2020-08-12 2020-06-30 13F IONIS PHARMACEUTICALS COM 462222100 278,812 -5,830 -2.05 16,439 22.15 0.3428
2020-05-15 2020-03-31 13F IONIS PHARMACEUTICALS COM 462222100 284,642 -117,155 -29.16 13,458 -44.56 0.3344
2020-01-14 2019-12-31 13F Ionis Pharmaceuticals COM 462222100 401,797 -7,510 -1.83 24,273 -1.02 0.3570
2019-10-31 2019-09-30 13F Ionis Pharmaceuticals COM 462222100 409,307 -37,008 -8.29 24,522 -14.51 0.3328
2019-07-31 2019-06-30 13F Ionis Pharmaceuticals COM 462222100 446,315 -4,479 -0.99 28,685 -21.61 0.3717
2019-04-30 2019-03-31 13F Ionis Pharmaceuticals COM 462222100 450,794 -86,029 -16.03 36,591 26.08 0.4885
2019-02-08 2018-12-31 13F Ionis Pharmaceuticals COM 462222100 536,823 -50,839 -8.65 29,021 -4.26 0.4349
2018-11-13 2018-09-30 13F Ionis Pharmaceuticals COM 462222100 587,662 -2,387 -0.40 30,312 23.28 0.3819
2018-08-13 2018-06-30 13F Ionis Pharmaceuticals COM 462222100 590,049 -1,784 -0.30 24,587 -5.75 0.3119
2018-05-14 2018-03-31 13F Ionis Pharmaceuticals COM 462222100 591,833 -249,891 -29.69 26,088 -38.38 0.3324
2018-02-13 2017-12-31 13F Ionis Pharmaceuticals COM 462222100 841,724 136,317 19.32 42,339 18.38 0.4807
2017-10-30 2017-09-30 13F Ionis Pharmaceuticals COM 462222100 705,407 -20,220 -2.79 35,764 -3.11 0.4113
2017-08-04 2017-06-30 13F Ionis Pharmaceuticals COM 462222100 725,627 -51,662 -6.65 36,913 18.13 0.4428
2017-04-28 2017-03-31 13F Ionis Pharmaceuticals COM 462222100 777,289 -45,221 -5.50 31,247 -20.57 0.3813
2017-01-30 2016-12-31 13F Ionis Pharmaceuticals COM 462222100 822,510 -315,039 -27.69 39,341 -5.61 0.5030
2016-10-31 2016-09-30 13F Ionis Pharmaceuticals COM 462222100 1,137,549 -188,571 -14.22 41,680 34.95 0.5004
2016-08-15 2016-06-30 13F/A-1 Ionis Pharmaceuticals COM 462222100 1,326,120 238,566 21.94 30,885 -29.88 0.3680
2016-07-29 2016-06-30 13F Ionis Pharmaceuticals COM 462222100 1,326,120 30,885
2016-04-29 2016-03-31 13F Ionis Pharmaceuticals COM 462222100 1,087,554 -23,911 -2.15 44,046 -36.01 0.5834
2016-01-29 2015-12-31 13F Ionis Pharmaceuticals COM 462222100 1,111,465 -67,163 -5.70 68,833 44.49 0.9332
2015-10-30 2015-09-30 13F Isis Pharmaceuticals COM 464330109 1,178,628 -47,843 -3.90 47,640 -32.50 0.6373
2015-07-31 2015-06-30 13F Isis Pharmaceuticals COM 464330109 1,226,471 -22,143 -1.77 70,583 -11.22 0.8313
2015-04-30 2015-03-31 13F Isis Pharmaceuticals COM 464330109 1,248,614 1,248,614 0.00 79,499 0.9344
2015-01-30 2014-12-31 13F Isis Pharmaceuticals COM 464330109 0 -1,832,109 -100.00 0 -100.00
2014-10-30 2014-09-30 13F Isis Pharmaceuticals COM 464330109 1,832,109 -30,794 -1.65 71,141 10.85 0.7896
2014-09-18 2014-06-30 13F/A-1 Isis Pharmaceuticals COM 464330109 1,862,903 601,200 47.65 64,177 17.72 0.6246
2014-07-30 2014-06-30 13F Isis Pharmaceuticals COM 464330109 1,862,903 64,177
2014-04-30 2014-03-31 13F Isis Pharmaceuticals COM 464330109 1,261,703 -398,181 -23.99 54,518 -17.56 0.7176
2014-01-30 2013-12-31 13F Isis Pharmaceuticals COM 464330109 1,659,884 325 0.02 66,130 6.15 0.8890
2013-10-30 2013-09-30 13F Isis Pharmaceuticals COM 464330109 1,659,559 -282,194 -14.53 62,300 19.41 0.7767
2013-07-30 2013-06-30 13F Isis Pharmaceuticals COM 464330109 1,941,753 1,941,753 52,175 0.7063
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-12 2026-03-31 13F IONIS PHARMACEUTICALS COM Call 1,000 0.00 75 -5.06 n/a n/a n/a
2026-02-12 2025-12-31 13F IONIS PHARMACEUTICALS COM Call 1,000 79 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.